Notably, men with both low TTP and low PTEN expression had the poorest disease-free survival (HR 2.98, 95% CI 1.05–8.46, P = 0.03), which remained significant in multivariable analysis adjusting for prognostic clinicopathological factors of Gleason score, tumor stage, and prostate-specific antigen (PSA) (HR 4.50, 95% CI 1.03–19.61, P = 0.045). This evidence concerns the gene KLK3 and neoplasm.